Nadjib Taouagh

Garches, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Journal: European journal of neurology

Published: February 27, 2026

Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.

Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.

Journal: European journal of neurology

Published: November 23, 2025

Causes of Death and Comorbidities in Adult Patients With Late-Onset Pompe Disease: A French Pompe Registry Retrospective Study.

Causes of Death and Comorbidities in Adult Patients With Late-Onset Pompe Disease: A French Pompe Registry Retrospective Study.

Journal: European journal of neurology

Published: May 20, 2025

Bulbar muscle impairment in patients with late onset Pompe disease: Insight from the French Pompe registry.

Bulbar muscle impairment in patients with late onset Pompe disease: Insight from the French Pompe registry.

Journal: European journal of neurology

Published: February 13, 2024

Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.

Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.

Journal: European journal of neurology

Published: January 10, 2024

Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.

Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.

Journal: Neurology

Published: July 22, 2022

Macroglossia: A potentially severe complication of late-onset Pompe disease.

Macroglossia: A potentially severe complication of late-onset Pompe disease.

Journal: European journal of neurology

Published: November 11, 2021

Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic.

Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic.

Journal: European journal of neurology

Published: October 09, 2021

Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.

Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.

Journal: Journal of inherited metabolic disease

Published: March 05, 2020

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.

Journal: Neurology

Published: February 15, 2019

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Journal: Journal of inherited metabolic disease

Published: February 11, 2018

Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.

Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.

Journal: Molecular genetics and metabolism

Published: May 30, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026